Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 29, 2023

Neoadjuvant Docetaxel, Epirubicin, and Cyclophosphamide With or Without Metformin in Patients With Breast Cancer With Metabolic Abnormality

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
Breast Cancer Res Treat 2022 Dec 16;[EPub Ahead of Print], J Huang, Y Tong, J Hong, O Huang, J Wu, J He, W Chen, Y Li, X Chen, K Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading